Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.35 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4864129 | 0.82 | GRIN2D (0.49) | ARG1CYP1A2ALOX15CYP2C19MEN1 | |
| SCHEMBL17592409 | 0.82 | ALDH1A1 (0.45) | ARG1CYP1A2MEN1KMT2AKDM4E | |
| SCHEMBL17592410 | 0.82 | ALDH1A1 (0.45) | ARG1CYP1A2MEN1KMT2AKDM4E | |
| SCHEMBL5511649 | 0.82 | ALDH1A1 (0.45) | ARG1CYP1A2MEN1KMT2AKDM4E | |
| SCHEMBL17592443 | 0.82 | ALDH1A1 (0.45) | ARG1CYP1A2MEN1KMT2AKDM4E | |
| SCHEMBL17592441 | 0.82 | ALDH1A1 (0.45) | ARG1CYP1A2MEN1KMT2AKDM4E | |
| SCHEMBL7694066 | 0.82 | ARG1 (0.44) | ARG1CYP1A2ALOX15CYP2C19CYP2D6 | |
| SCHEMBL7442641 | 0.82 | ARG1 (0.58) | ARG1CYP1A2ALOX15CYP2C19CYP2D6 | |
| SCHEMBL7411388 | 0.82 | ARG1 (0.58) | ARG1CYP1A2ALOX15CYP2C19CYP2D6 | |
| SCHEMBL3781408 | 0.82 | ARG1 (0.58) | ARG1CYP1A2ALOX15CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ARG1 136/4885CYP1A2 50/4885ALOX15 2070/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | ARG1 136/4885CYP1A2 50/4885ALOX15 2070/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ARG1 136/4885CYP1A2 50/4885ALOX15 2070/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ARG1 136/4885CYP1A2 50/4885ALOX15 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.